저자:
Monali Tayade, Sampada Kulkarni
무료 PDF 다운로드
임상시험수탁기관 시장 규모 및 점유율 2026-2035
보고서 ID: GMI3012
|
발행일: October 2026
|
보고서 형식: PDF/엑셀/대시보드/플랫폼
라이선스 옵션 살펴보기:
임상시험수탁기관 시장
이 보고서의 무료 샘플을 받으세요
이 보고서의 무료 샘플을 받으세요
임상시험수탁기관 시장
Is your requirement urgent? Please give us your business email
for a speedy delivery!
Contract Research Organization (CRO) Market Size
The contract research organization (CRO) market was valued at USD 57.5 billion in 2025, is projected to reach USD 61.2 billion in 2026, and is expected to expand at a 6.5% CAGR from 2026 to 2035, reaching USD 107.6 billion by 2035.
임상시험수탁기관 시장 주요 내용
시장 선도 기업: IQVIA Holdings는 2025년 시장 점유율 15.5% 초과를 기록하며 선두를 차지했습니다.
주요 기업: 이 시장의 상위 5개 기업은 IQVIA Holdings, ICON plc, Syneos Health, Labcorp Drug Development, Medpace Holdings이며, 이들 기업의 2025년 합산 시장 점유율은 69.3%였습니다.
The contract research organization (CRO) market is being reshaped by sponsor efforts to preserve development velocity while limiting fixed clinical operations capacity. Expanding biologics, oncology, cell and gene therapy, and biosimilar pipelines favor outsourced partners that can combine scientific depth, global execution, and data-enabled trial management within a single accountable delivery model.
GMI Analyst View
Based on our discussions with industry experts and demand-side pipeline modeling, the global contract research organization (CRO) market is on track to reach USD 78.80 billion by 2030-a mid-decade inflection point shaped by the concurrent maturation of GLP-1, CAR-T, and biosimilar Phase III programs alongside the accelerating integration of AI-assisted trial management into full-service CRO platforms.
Contract Research Organization (CRO) Market Trends, Growth Drivers & GMI Forecast Outlook
The contract research organization sector enters the forecast decade with expanding oncology and biologics trial mandates raising baseline service demand, while concurrent pressure from data-privacy compliance obligations and trial-cost inflation is compressing margins and shifting sponsor preference toward technology-enabled and full-service partners with demonstrable regulatory track records.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
R&D budgets matter to CRO demand not merely because they increase spending, but because complex development portfolios strain internal coordination across sites, laboratories, data systems, and regulatory workstreams. Sponsors can transfer that operating burden to partners able to link enrollment operations, medical monitoring, biostatistics, and submission-ready documentation, making execution reliability a central procurement criterion.
The expansion in study starts also increases the premium on therapeutic specialization. Oncology and rare-disease studies frequently require dispersed site networks, biomarker-informed enrollment, and adaptive operating models. CROs that combine established investigator access with validated digital workflows can convert protocol complexity into more durable program relationships rather than isolated transactional assignments.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Compliance exposure is becoming a commercial differentiator as trial programs generate increasingly granular patient, biomarker, and real-world datasets. Providers must fund resilient data governance and cybersecurity capabilities while maintaining rapid cross-border data access, creating a cost burden that is more readily absorbed by established platforms with standardized controls.
Recruitment pressure compounds that challenge. Delayed enrollment can disrupt site utilization, alter resource plans, and weaken the economics of fixed-fee engagements. Hybrid and decentralized approaches may expand access, but they do not eliminate the operational difficulty of recruiting narrowly defined populations for complex oncology, rare-disease, and advanced-therapy protocols.
GMI Analyst View
We see outsourcing decisions shifting toward a capability-integrated model in which sponsors prioritize accountability across clinical operations, data, laboratory work, and regulatory execution. This favors providers that can demonstrate therapeutic depth and consistent delivery, while mid-tier CROs face a sharper need to differentiate through specialist expertise, flexibility, or regional execution strength.
Contract Research Organization (CRO) Market Segment Analysis
By Service Type
Clinical research services across Phase I-IV generated USD 27.60 billion in 2025 and are projected to expand at a 6.8% CAGR from 2026 to 2035. Within the contract research organization (CRO) market, this category remains central because sponsors increasingly delegate integrated trial execution rather than fragmenting clinical operations, data management, medical monitoring, and site oversight among multiple vendors.
Laboratory services held a 23.0% revenue share in 2025 and are projected to reach USD 24.30 billion by 2035. Demand is strengthened by biomarker-intensive oncology protocols, biologics development, companion diagnostics, and the specialized bioanalytical requirements of cell and gene therapies, all of which elevate the value of accredited central laboratory infrastructure and scientific interpretation capabilities.
Early phase development services generated USD 10.35 billion in 2025 and are expected to grow at a 6.9% CAGR from 2026 to 2035. Emerging biotechnology sponsors frequently lack internal toxicology, pharmacokinetic, and early clinical operations capacity, making integrated discovery-to-IND support attractive where program speed and scientific continuity are important to financing, regulatory submission, and partner-selection milestones.
Regulatory consulting is projected to reach USD 10.30 billion by 2035 and held an 11.0% revenue share in 2025. Although smaller than core clinical operations, the category is strategically important because regulatory advice often shapes development design, agency engagement, and the broader scope of a sponsor's outsourced relationship, particularly for novel modalities and multi-regional filing strategies.
By End Use
Pharma & biopharma companies generated USD 39.10 billion in CRO service revenue in 2025 and are expected to advance at a 6.6% CAGR from 2026 to 2035. Patent pressure, increasingly specialized pipelines, and lean operating structures are reinforcing reliance on external delivery partners, especially among sponsors developing biologics, advanced therapies, and complex oncology assets.
Medical device companies held an 18.0% revenue share in 2025 and are projected to reach USD 19.20 billion by 2035. More demanding clinical evidence expectations for implantables, software-enabled devices, diagnostics, and combination products are increasing the need for partners that can navigate both clinical operations and device-specific regulatory science.
Academic institutes accounted for a 14.0% revenue share in 2025 and are expected to reach USD 15.00 billion by 2035. Investigator-initiated studies increasingly require professional data management, biostatistics, electronic data capture, and regulatory support as institutional review, data-sharing, and protocol-governance requirements become more operationally demanding.
By Therapeutic Area
Oncology generated USD 20.13 billion in 2025 and is projected to grow at a 7.4% CAGR from 2026 to 2035. The category's prominence reflects biomarker-driven designs, complex safety monitoring, specialist-site requirements, and the need to coordinate enrollment across dispersed patient populations, making therapeutic expertise and integrated operational execution decisive differentiators.
Clinical pharmacology held a 15.0% revenue share in 2025 and is expected to reach USD 16.20 billion by 2035. Early human studies for biologics, oligonucleotides, and novel small molecules require specialized investigative sites, bioanalytical capability, and close safety oversight, supporting demand for CROs with dedicated Phase I infrastructure.
Cardiology generated USD 6.90 billion in 2025 and is expected to expand at a 6.2% CAGR from 2026 to 2035. Large cardiovascular outcomes programs can require long follow-up periods, substantial patient cohorts, and endpoint-adjudication coordination, favoring full-service providers with deep site networks and experience managing event-driven studies.
Infectious disease held a 10.0% revenue share in 2025 and is projected to reach USD 10.00 billion by 2035. Demand is normalizing from pandemic-era activity, yet preparedness initiatives, vaccine work, and continuing programs in respiratory and chronic infectious conditions sustain a meaningful need for CROs experienced in adaptive and platform-based trial models.
Neurology generated USD 5.75 billion in 2025 and is projected to grow at a 6.8% CAGR from 2026 to 2035. Complex cognitive assessments, challenging patient identification, and evolving regulatory expectations for disease-modifying therapies create a premium for CROs that can align clinical operations with therapeutic-area-specific endpoint and safety requirements.
Gastro & hepatology held an 8.0% revenue share in 2025 and is projected to reach USD 8.30 billion by 2035. Development activity in inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, and hepatitis programs supports demand for networks with endoscopy, liver-biopsy, and specialist patient-access capabilities.
Ophthalmology generated USD 2.88 billion in 2025 and is expected to grow at a 6.9% CAGR from 2026 to 2035. The segment rewards providers with retinal imaging, reading-center infrastructure, ocular investigator relationships, and regulatory experience across pharmaceutical and device development, creating meaningful barriers to entry for generalist clinical operations teams.
Other therapeutic areas held a 5.0% revenue share in 2025 and are projected to reach USD 4.90 billion by 2035. These programs provide a stable base of work across mature indications, although their demand profile is less influenced by the high-complexity pipeline expansion evident in oncology, advanced neurology, and specialty metabolic disease.
GMI Analyst View
We view therapeutic specialization as a key dividing line in CRO competition. The most demanding programs increasingly require a combination of scientific credibility, validated operating processes, specialist sites, and technology infrastructure, encouraging sponsors to deepen relationships with partners that can support a development asset across several stages rather than only one discrete service need.
Contract Research Organization (CRO) Market Regional Analysis
North America Contract Research Organization (CRO) Market Analysis
The North America contract research organization (CRO) market generated USD 24.84 billion in 2025 and is projected to grow at a 5.9% CAGR from 2026 to 2035. Its mature outsourcing environment is supported by the concentration of pharmaceutical and biotechnology sponsors, established regulatory pathways, sophisticated academic medical centers, and extensive investigator networks. Growth remains comparatively moderated by the region's high existing outsourcing penetration rather than a loss of strategic importance.
Europe Contract Research Organization (CRO) Market Analysis
Europe is projected to reach USD 30.80 billion by 2035 and held a 29.5% global revenue share in 2025. The region combines established clinical infrastructure with broad patient diversity, while harmonized processes under the EU Clinical Trials Regulation can improve the operational appeal of multi-country programs. Europe remains particularly relevant for sponsors requiring coordinated regulatory, site, and patient-access capabilities across several national markets.
Asia Pacific Contract Research Organization (CRO) Market Analysis
Asia Pacific generated USD 10.35 billion in 2025 and is expected to expand at a 7.2% CAGR from 2026 to 2035. Regulatory alignment with international standards, large and diverse patient populations, and expanding domestic biopharma innovation are increasing the region's role in global registration programs. The opportunity favors CROs able to connect local regulatory expertise and site execution with globally consistent quality and data-management practices.
Latin America Contract Research Organization (CRO) Market Analysis
Latin America is projected to reach USD 5.90 billion by 2035 and represented a 5.5% global revenue share in 2025. The region offers access to diverse patient populations and can strengthen multicontinental enrollment strategies in cardiometabolic disease, oncology, infectious disease, and other high-burden indications. Its commercial relevance depends on CRO capability in local site activation, regulatory coordination, and sustained investigator engagement.
Middle East & Africa Contract Research Organization (CRO) Market Analysis
The Middle East & Africa contract research organization (CRO) market generated USD 2.18 billion in 2025 and is projected to reach USD 4.20 billion by 2035. Expanding clinical research infrastructure, advancing regulatory frameworks, and sponsor interest in representative global datasets are broadening the region's role in international programs. Providers with durable local partnerships and jurisdiction-specific operating knowledge are positioned to benefit as trial activity becomes more geographically diversified.
GMI Analyst View
We believe regional strategy is becoming less about securing lower-cost enrollment capacity and more about creating registration-relevant evidence across diverse populations. Providers that can integrate local execution with global quality standards will be better placed to win programs where geographic coverage is integral to regulatory and commercial strategy.
Contract Research Organization (CRO) Market Share & Competitive Landscape
The contract research organization (CRO) market share landscape is moderately concentrated at the upper tier, with the top three CRO operators collectively holding a 43.6% revenue share in 2025. Scale matters because large global providers can combine broad site access, data platforms, laboratory capabilities, and regulatory support; however, specialty and regional CROs remain relevant where therapeutic focus, client proximity, or jurisdiction-specific expertise carries greater weight than global breadth.
IQVIA Holdings held a 15.5% revenue share in 2025. Its positioning is supported by integrated data assets, technology-enabled trial operations, and the ability to coordinate multinational studies for sponsors that require large-scale enrollment, real-world evidence, and end-to-end clinical development services.
ICON plc held a 14.3% revenue share in 2025. The company competes through therapeutic-area depth, global delivery capacity, and functional-service-provider capabilities that address sponsors seeking a flexible model between fully outsourced development and retained internal operations.
Pharmaceutical Product Development (PPD), the clinical research business of Thermo Fisher Scientific, held a 13.8% revenue share in 2025. Its affiliation with a broader life sciences platform supports an integrated proposition spanning clinical development, bioanalytical work, and supply-chain-adjacent capabilities that can be particularly attractive to biotechnology and specialty-pharma sponsors.
Competitive intensity extends beyond the largest full-service operators. Syneos Health combines clinical development with commercialization capabilities, while Laboratory Corporation of America Holdings leverages laboratory assets for biomarker-intensive programs. Parexel International retains regulatory consulting depth, Medpace Holdings emphasizes integrated in-house scientific functions, and Charles River Laboratories is positioned at the discovery-to-early-development interface. Specialist providers including Caidya, Iris Pharma, Lexitas Pharma Services, and Ora compete through focused therapeutic expertise, while CMIC HOLDINGS, EPS Holdings, and WuXi Clinical provide important regional execution capabilities.
Recent Industry Developments
Novotech announced an agreement to acquire Agilex Biolabs, adding specialist bioanalytical capabilities in Australia to support integrated clinical and laboratory services for biotechnology and pharmaceutical sponsors. The transaction reflects the strategic value of combining regional early-phase capacity with bioanalytical expertise in a market that is increasingly relevant to global development programs [5]Novotech. "Novotech to acquire Agilex Biolabs." novotech-cro.com.
hVIVO announced the acquisition of CRS Clinical Research Services Berlin GmbH, extending its German clinical network with a specialist Phase I/II facility. The development illustrates continuing interest in consolidating targeted early-stage clinical capacity and disease-focused site infrastructure within European CRO operations [6]GlobeNewswire. "hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets." globenewswire.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
자주 묻는 질문 (FAQs):
조사 방법론, 데이터 출처 및 검증 절차
이 보고서는 업계 관계자와의 직접 대화, 자체 모델링, 엄격한 교차 검증을 중심으로 설계된 체계적인 조사 절차를 바탕으로 합니다. 단순한 문헌 조사에만 의존하지 않습니다.
당사의 6단계 조사 절차
1. 조사 설계 및 애널리스트 감독
GMI의 조사 방법론은 전문 인력의 지식, 엄격한 검증, 완전한 투명성을 토대로 합니다. 보고서의 모든 인사이트, 추세 분석 및 전망은 해당 시장의 특성을 이해하는 숙련된 애널리스트가 작성합니다.
당사는 업계 관계자 및 전문가와 직접 소통하는 광범위한 1차 조사에, 신뢰성이 확인된 글로벌 출처를 활용한 포괄적인 2차 조사를 결합합니다. 정량적 영향 분석을 적용해 신뢰할 수 있는 전망을 제공하며, 최초 데이터 출처부터 최종 분석 결과까지 추적 가능성을 유지합니다.
2. 1차 조사
1차 조사는 당사 방법론의 핵심으로, 전체 인사이트의 약 80%를 차지합니다. 분석의 정확성과 깊이를 확보하기 위해 업계 관계자와 직접 소통합니다. 체계적인 인터뷰 프로그램은 지역 및 글로벌 시장을 포괄하며 최고경영진, 이사 및 분야별 전문가의 의견을 수집합니다. 이를 통해 전략, 운영 및 기술 측면의 관점을 확보하고 균형 잡힌 인사이트와 신뢰성 있는 시장 전망을 도출합니다.
3. 데이터 마이닝 및 시장 분석
데이터 마이닝은 조사 절차의 중요한 부분으로, 전체 방법론에서 약 20%를 차지합니다. 주요 기업의 매출 점유율 분석을 통해 시장 구조를 분석하고 업계 동향을 파악하며 거시경제 요인을 평가합니다. 유료 및 무료 출처에서 관련 데이터를 수집해 신뢰성 있는 데이터베이스를 구축합니다. 이 정보는 1차 조사와 시장 규모 추정을 뒷받침하도록 통합되며, 유통업체, 제조업체 및 협회 등 주요 이해관계자의 검증을 거칩니다.
4. 시장 규모 추정
당사는 상향식 접근법으로 시장 규모를 추정합니다. 1차 인터뷰를 통해 직접 확보한 기업 매출 데이터와 제조업체의 생산량, 설치 또는 도입 통계를 출발점으로 삼습니다. 이러한 자료를 지역 시장별로 합산하여 실제 산업 활동에 근거한 글로벌 시장 추정치를 산출합니다.
5. 전망 모델 및 주요 가정
모든 전망에는 다음 사항을 명시합니다.
✓ 주요 성장 동인과 예상 영향
✓ 성장 제약 요인과 영향 완화 시나리오
✓ 규제 관련 가정과 정책 변경 위험
✓ 기술 도입 곡선의 매개변수
✓ 거시경제 가정(GDP 성장률, 인플레이션, 환율)
✓ 경쟁 구도와 시장 진입·퇴출 전망
6. 검증 및 품질 보증
최종 단계에서는 분야별 전문가가 선별된 데이터를 직접 검토하여 자동화 시스템이 놓칠 수 있는 미묘한 차이와 맥락상의 오류를 파악합니다. 이러한 전문가 검토는 중요한 품질 보증 단계로서, 데이터가 조사 목적과 해당 분야의 기준에 부합하는지 확인합니다.
당사의 3중 검증 절차는 데이터의 신뢰성을 최대한 높입니다.
✓ 통계적 검증
✓ 전문가 검증
✓ 실제 시장 상황과의 대조
신뢰와 공신력
검증된 데이터 출처
업계 전문 간행물
산업 저널, 업계 간행물 및 전문 매체
산업 데이터베이스
자체 및 제3자 시장 데이터베이스
규제 관련 제출 서류
정부 조달 기록 및 정책 문서
학술 연구
대학 연구 및 전문 연구기관 보고서
기업 보고서
연례보고서, 투자자 설명자료 및 공시 서류
전문가 인터뷰
최고경영진, 조달 책임자 및 기술 전문가
GMI 아카이브
20개 이상의 산업 분야에 걸쳐 발행된 13,000건 이상의 조사 보고서
무역 데이터
수출입 물량, HS 코드 및 통관 기록
조사 및 평가 항목
이 보고서의 모든 데이터는 1차 인터뷰, 실제 데이터를 쌓아 올리는 상향식 모델링, 엄격한 교차 검증을 통해 확인됩니다. 당사의 조사 절차 자세히 보기 →